JP2002542341A5 - - Google Patents

Download PDF

Info

Publication number
JP2002542341A5
JP2002542341A5 JP2000611949A JP2000611949A JP2002542341A5 JP 2002542341 A5 JP2002542341 A5 JP 2002542341A5 JP 2000611949 A JP2000611949 A JP 2000611949A JP 2000611949 A JP2000611949 A JP 2000611949A JP 2002542341 A5 JP2002542341 A5 JP 2002542341A5
Authority
JP
Japan
Prior art keywords
formulation
lipid
compound
group
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000611949A
Other languages
English (en)
Japanese (ja)
Other versions
JP5117648B2 (ja
JP2002542341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2000/000451 external-priority patent/WO2000062813A2/en
Publication of JP2002542341A publication Critical patent/JP2002542341A/ja
Publication of JP2002542341A5 publication Critical patent/JP2002542341A5/ja
Application granted granted Critical
Publication of JP5117648B2 publication Critical patent/JP5117648B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000611949A 1999-04-20 2000-04-20 カチオン性ｐｅｇ脂質および使用方法。 Expired - Fee Related JP5117648B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13015199P 1999-04-20 1999-04-20
US60/130,151 1999-04-20
PCT/CA2000/000451 WO2000062813A2 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012017765A Division JP2012122075A (ja) 1999-04-20 2012-01-31 カチオン性ｐｅｇ脂質および使用方法

Publications (3)

Publication Number Publication Date
JP2002542341A JP2002542341A (ja) 2002-12-10
JP2002542341A5 true JP2002542341A5 (pl) 2007-06-07
JP5117648B2 JP5117648B2 (ja) 2013-01-16

Family

ID=22443303

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000611949A Expired - Fee Related JP5117648B2 (ja) 1999-04-20 2000-04-20 カチオン性ｐｅｇ脂質および使用方法。
JP2012017765A Pending JP2012122075A (ja) 1999-04-20 2012-01-31 カチオン性ｐｅｇ脂質および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012017765A Pending JP2012122075A (ja) 1999-04-20 2012-01-31 カチオン性ｐｅｇ脂質および使用方法

Country Status (5)

Country Link
EP (1) EP1173600A2 (pl)
JP (2) JP5117648B2 (pl)
AU (1) AU783647B2 (pl)
CA (1) CA2370690A1 (pl)
WO (1) WO2000062813A2 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4656675B2 (ja) 1997-05-14 2011-03-23 ユニバーシティー オブ ブリティッシュ コロンビア 脂質小胞への荷電した治療剤の高率封入
AU2001254548B2 (en) * 2000-04-20 2006-09-28 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
WO2002034236A2 (en) * 2000-10-25 2002-05-02 The University Of British Columbia Lipid formulations for target delivery
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
EP1603535A4 (en) * 2003-03-18 2008-10-15 Ethicon Inc AROMATASE HEMMER DIAGNOSIS AND THERAPY
SG190613A1 (en) 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
JP4842821B2 (ja) * 2003-09-15 2011-12-21 プロチバ バイオセラピューティクス インコーポレイティッド ポリエチレングリコール修飾脂質化合物およびその使用
FR2870741B1 (fr) 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
EP1766035B1 (en) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
US8765181B2 (en) * 2005-09-09 2014-07-01 Beijing Diacrid Medical Technology Co., Ltd Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids
AU2006308765B2 (en) 2005-11-02 2013-09-05 Arbutus Biopharma Corporation Modified siRNA molecules and uses thereof
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2008342535B2 (en) 2007-12-27 2015-02-05 Arbutus Biopharma Corporation Silencing of polo-like kinase expression using interfering RNA
CA2721380A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
US9222086B2 (en) 2009-09-23 2015-12-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
PT3338765T (pt) 2009-12-01 2019-03-18 Translate Bio Inc Derivado de esteróide adequado para a administração de arnm em doenças genéticas humanas
CA2799091A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
CA2802994A1 (en) 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions and methods for treating inflammatory conditions
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
BR112013031553A2 (pt) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
US11073451B2 (en) 2011-12-19 2021-07-27 Kode Biotech Limited Biocompatible method of functionalising substrates with inert surfaces
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP3988104A1 (en) 2012-02-24 2022-04-27 Arbutus Biopharma Corporation Trialkyl cationic lipids and methods of use thereof
ES2644778T3 (es) * 2012-03-16 2017-11-30 Merck Patent Gmbh Administración dirigida de lípidos-aminoácidos
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
IL305374A (en) 2013-03-14 2023-10-01 Ethris Gmbh CFTR mRNA Assemblies and Related Methods and Uses
US9957499B2 (en) 2013-03-14 2018-05-01 Translate Bio, Inc. Methods for purification of messenger RNA
US20160151284A1 (en) 2013-07-23 2016-06-02 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
CA2928188A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for argininosuccinate synthetase deficiency
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
ES2750661T3 (es) 2014-04-25 2020-03-26 Translate Bio Inc Métodos para la purificación de ARN mensajero
AU2015328012A1 (en) 2014-10-02 2017-05-11 Arbutus Biopharma Corporation Compositions and methods for silencing Hepatitis B virus gene expression
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
CA2995995A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
EP3585417B1 (en) 2017-02-27 2023-02-22 Translate Bio, Inc. Method of making a codon-optimized cftr mrna
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
GB201910299D0 (en) 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses
WO2021125805A1 (ko) * 2019-12-20 2021-06-24 주식회사 삼양홀딩스 폴리락트산염을 포함하는 약물전달용 나노입자 조성물 제조용 키트
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
WO2023144798A1 (en) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4215820B2 (ja) * 1995-06-07 2009-01-28 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 診断的および治療的使用のための新規な標的化組成物
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
WO1998016201A1 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
WO1998046208A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Hair follicle dna delivery system
WO1998051285A2 (en) * 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
WO1999005303A1 (en) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
JP2002518313A (ja) * 1998-06-19 2002-06-25 ジエンザイム コーポレイション カチオン性両親媒性ミセル複合体
AU2620000A (en) * 1999-01-21 2000-08-07 Georgetown University Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery
EP1046394A3 (en) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Novel compositions useful for delivering compounds into a cell
ATE374785T1 (de) * 2000-03-02 2007-10-15 Mitsubishi Pharma Corp Gpib-gebundenes konstrukt und verwendungen davon

Similar Documents

Publication Publication Date Title
JP2002542341A5 (pl)
EP0789564B1 (en) Polynucleotide compositions
US8324365B2 (en) Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
US6440743B1 (en) Methods of using polynucleotide compositions
ES2323701T3 (es) Composiciones farmaceuticas que comprenden copolimeros de bloque sensibles al ph y un farmaco hidrofobo.
US8182802B2 (en) Composition of polymers
CN1893924A (zh) 一种新的阳离子脂质聚合物作为生物相容性基因递送剂
US8147868B2 (en) Physiologically active polypeptide- or protein-encapsulating polymer micelles, and method for production of the same
KR102198736B1 (ko) 생체 내 약물 전달을 위한 지질 나노입자 및 이의 용도
CA2717370A1 (en) Biodegradable cross-linked branched poly (alkylene imines)
Nicolazzi et al. Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time
EP2087912A1 (en) ENVIRONMENT-RESPONDING siRNA CARRIER USING DISULFIDE-BRIDGED POLYMERIC MICELLE
WO1999006055A1 (en) Polynucleotide compositions
JPWO2020219941A5 (pl)
JP2009542582A5 (pl)
ES2270171T3 (es) Polimeros tribloques para la administracion de un agente o de un medicamento a base de nanosferas.
JP2004515228A (ja) 細胞への導入を容易にするジェミニ型のペプチド系界面活性化合物
US20210393523A1 (en) Aromatic ring substituted amphiphilic polymers as drug delivery systems
Sideratou et al. Design of functional dendritic polymers for application as drug and gene delivery systems
JP2023540806A (ja) 骨格筋への送達プラットフォームおよび使用の方法
WO2020116640A1 (ja) 薬物複合体、ポリマー複合体及び薬物送達用組成物
EP1003527A1 (en) Polynucleotide compositions
US20230301913A1 (en) Silyl lipids suitable for enhanced delivery of anti-viral therapeutics
WO2024110492A1 (en) Novel carriers for nucleic acid and/or protein delivery
Uglea et al. Dendrimers: A New Tool for Drug Administration